High‐Z‐Sensitized Radiotherapy Synergizes with the Intervention of the Pentose Phosphate Pathway for In Situ Tumor Vaccination
Source abstract
Abstract
Abstract In situ tumor vaccination is preliminarily pursued to strengthen antitumor immune response. Immunogenic tumor cell death spontaneously releases abundant antigens and adjuvants for activation of dendritic cells, providing a paragon opportunity for establishing efficient in situ vaccination. Herein, Phy@PLGdH nanosheets are constructed by integrating physcion (Phy, an inhibitor of the pentose phosphate pathway (PPP)) with layered gadolinium hydroxide (PLGdH) nanosheets to boost radiation‐therapy (RT)‐induced immunogenic cell death (ICD) for potent in situ tumor vaccination. It is first observed that sheet‐like PLGdH can present superior X‐ray deposition and tumor penetrability, exhibiting improved radiosensitization in vitro and in vivo. Moreover, the destruction of cellular nicotinamide adenine dinucleotide phosphate (NADPH) and nucleotide homeostasis by Phy‐mediated PPP intervention can further amplify PLGdH‐sensitized RT‐mediated oxidative stress and DNA damage, which correspondingly results in effective ICD and enhance the immunogenicity of irradiated tumor cells. Consequently, Phy@PLGdH‐sensitized RT successfully primes robust CD8+‐T‐cell‐dependent antitumor immunity to potentiate checkpoint blockade immunotherapies against primary and metastatic tumors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Pharmaceutical Biotechnology Medical School and School of Life Science and Jiangsu Key Laboratory for Nano Technology Nanjing University Nanjing 210093 China
Department of Urology Zhejiang Provincial People's Hospital Hangzhou Zhejiang 310014 China
References (72)
Show source-provided references
1. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
2. 10.1038/s43018-021-00247-z10.1038/s43018-021-00247-z ↗
3. 10.1002/jcp.2955110.1002/jcp.29551 ↗
4. 10.1080/21645515.2015.104977910.1080/21645515.2015.1049779 ↗
5. 10.1038/s41591-019-0410-x10.1038/s41591-019-0410-x ↗
6. 10.1002/adma.20210062810.1002/adma.202100628 ↗
7. 10.1126/sciadv.abf124410.1126/sciadv.abf1244 ↗
8. 10.3390/vaccines703010010.3390/vaccines7030100 ↗
9. 10.1038/s41590-019-0561-410.1038/s41590-019-0561-4 ↗
10. 10.1126/sciadv.abb522310.1126/sciadv.abb5223 ↗
11. 10.3389/fimmu.2017.0022910.3389/fimmu.2017.00229 ↗
12. 10.1016/j.currproblcancer.2015.10.00110.1016/j.currproblcancer.2015.10.001 ↗
13. 10.1016/j.drudis.2020.11.02910.1016/j.drudis.2020.11.029 ↗
14. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
15. 10.1038/s41568-021-00386-610.1038/s41568-021-00386-6 ↗
16. 10.1002/smll.20200623110.1002/smll.202006231 ↗
17. 10.1002/adma.20190491410.1002/adma.201904914 ↗
18. 10.1101/gad.119990410.1101/gad.1199904 ↗
19. 10.1016/S1470-2045(19)30326-210.1016/S1470-2045(19)30326-2 ↗
20. 10.1016/j.ijrobp.2021.06.04110.1016/j.ijrobp.2021.06.041 ↗
21. 10.1093/annonc/mdz451.03410.1093/annonc/mdz451.034 ↗
22. 10.1007/s13238-014-0082-810.1007/s13238-014-0082-8 ↗
23. 10.1038/s43018-020-0086-710.1038/s43018-020-0086-7 ↗
24. 10.1016/j.tibs.2014.06.00510.1016/j.tibs.2014.06.005 ↗
25. 10.1002/btm2.1018410.1002/btm2.10184 ↗
26. 10.1038/s41556-020-0496-x10.1038/s41556-020-0496-x ↗
27. 10.1016/j.clon.2014.02.00310.1016/j.clon.2014.02.003 ↗
28. 10.1101/cshperspect.a04059210.1101/cshperspect.a040592 ↗
29. 10.1038/onc.2017.22710.1038/onc.2017.227 ↗
30. 10.1016/j.molcel.2015.06.01710.1016/j.molcel.2015.06.017 ↗
31. 10.1016/j.freeradbiomed.2012.05.00610.1016/j.freeradbiomed.2012.05.006 ↗
32. 10.1038/s41467-019-08921-810.1038/s41467-019-08921-8 ↗
33. 10.1016/j.mce.2019.11059510.1016/j.mce.2019.110595 ↗
34. 10.1016/S0014-5793(99)00924-210.1016/S0014-5793(99)00924-2 ↗
35. 10.1038/s41467-020-15308-710.1038/s41467-020-15308-7 ↗
36. 10.1038/emboj.2010.33010.1038/emboj.2010.330 ↗
37. 10.1016/j.gene.2017.09.00510.1016/j.gene.2017.09.005 ↗
38. 10.1039/b823172a10.1039/b823172a ↗
39. 10.1002/adfm.20090105110.1002/adfm.200901051 ↗
40. 10.1002/adhm.20150044110.1002/adhm.201500441 ↗
41. 10.1016/j.chempr.2018.02.01210.1016/j.chempr.2018.02.012 ↗
42. 10.1158/1078-0432.CCR-19-132110.1158/1078-0432.CCR-19-1321 ↗
43. 10.1093/annonc/mdx72710.1093/annonc/mdx727 ↗
44. 10.1038/s41467-020-17414-y10.1038/s41467-020-17414-y ↗
45. 10.1002/adma.20180332210.1002/adma.201803322 ↗
46. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
47. 10.1016/j.immuni.2020.05.01310.1016/j.immuni.2020.05.013 ↗
48. 10.1038/s41573-018-0011-210.1038/s41573-018-0011-2 ↗
49. 10.1016/j.ccr.2013.12.00410.1016/j.ccr.2013.12.004 ↗
50. 10.1038/s41467-018-04703-w10.1038/s41467-018-04703-w ↗
51. 10.1070/RCR492010.1070/RCR4920 ↗
52. 10.1002/adma.20180646110.1002/adma.201806461 ↗
53. 10.1021/cm701928410.1021/cm7019284 ↗
54. 10.1021/ja807050e10.1021/ja807050e ↗
55. 10.1002/anie.20060250210.1002/anie.200602502 ↗
56. 10.1021/acsami.1c0885710.1021/acsami.1c08857 ↗
57. 10.3390/cancers1101011210.3390/cancers11010112 ↗
58. 10.1126/science.aaw547310.1126/science.aaw5473 ↗
59. 10.1038/s41568-021-00383-910.1038/s41568-021-00383-9 ↗
60. 10.1002/adma.20210652010.1002/adma.202106520 ↗
61. 10.1038/onc.2015.34810.1038/onc.2015.348 ↗
62. 10.1089/ars.2013.569010.1089/ars.2013.5690 ↗
63. 10.3390/ijms2103093710.3390/ijms21030937 ↗
64. 10.3389/fphar.2018.0004310.3389/fphar.2018.00043 ↗
65. 10.1667/RR13828.110.1667/RR13828.1 ↗
66. 10.1089/ars.2010.379710.1089/ars.2010.3797 ↗
67. 10.1016/j.cels.2018.04.00910.1016/j.cels.2018.04.009 ↗
68. 10.1016/j.isci.2019.08.04710.1016/j.isci.2019.08.047 ↗
69. 10.1002/1522-2586(200008)12:2<205::AID-JMRI1>3.0.CO;2-P10.1002/1522-2586(200008)12:2<205::AID-JMRI1>3.0.CO;2-P ↗
70. 10.1038/ncb325510.1038/ncb3255 ↗
71. 10.3109/0886022X.2011.59991110.3109/0886022X.2011.599911 ↗
72. 10.1039/C7DT03729E10.1039/C7DT03729E ↗